Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian CancerIgnace Vergote, Peter G. Rose, James J. Burke et al.|International Journal of Gynecological Cancer|2010Cited by 62
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndromeAzra Raza, Mikkael A. Sekeres, Naomi Galili et al.|Cancer|2011Cited by 44
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)Azra Raza, Ruben A. Mesa, Naomi Galili et al.|Journal of Hematology & Oncology|2012Cited by 27
Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung CancerLecia V. Sequist, Thomas J. Lynch, Panos Fidias et al.|Journal of Thoracic Oncology|2009Cited by 19
Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Azra Raza, Mikkael A. Sekeres, Naomi Galili et al.|Blood|2010Cited by 2